XTL Biopharmaceuticals Ltd. - American Depositary Shares (XTLB)

Относно

XTL Biopharmaceuticals Ltd., incorporated on March 9, 1993, is a biopharmaceutical company. The Company is engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company’s developed drug candidate is hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren’s syndrome (SS). Its hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. Its rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM).